Skip to main content
Clinical Trials/NCT05826769
NCT05826769
Recruiting
Not Applicable

To Assess the Efficacy of Early Administration of Energy Enriched and Protein Enriched Formula in Post Cardiac Repair Infants: a Randomized Controlled Trial, Comparative Study

King Faisal Specialist Hospital & Research Centre, Jeddah1 site in 1 country60 target enrollmentJuly 21, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Congenital Heart Disease in Children
Sponsor
King Faisal Specialist Hospital & Research Centre, Jeddah
Enrollment
60
Locations
1
Primary Endpoint
after admission in ICU, will measure the Tolerability
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Congenital heart disease (CHD) is a public health problem, A substantial percentage of infants and toddlers with CHD undergo cardiopulmonary bypass surgery. Undernutrition affects up to 90% of these patients, and it's contributed to worse surgical and neurological outcomes. Infants with CHD are typically delivered at full term with a normal birth weight. However, as time passes, their development may become stunted. There are no negotiated guidelines for nutritional monitoring and intervention in this age bracket of infants. Through the use of Energy Enriched and Protein Enriched nutrition formula during the postoperative phase, this has shown to be well tolerated and support in delivering higher nutrition intakes within the first days after surgery. The objective of this research is to assess the long term outcome of patients who have had energy- and protein-rich nutrition formulas post cardiac surgery. An open, 2-arm, randomized controlled trials will be conducted to assess the efficacy of early administration of energy enriched and protein enriched formula in post cardiac repair infants. The expected primary outcome is that intervention group will have good tolerance to feeding and the secondary outcome is the significant weight gain rate (weight velocity) in comparing to control groups

Detailed Description

Due to a high incidence of 9/1000 live births, congenital heart disease (CHD) is a public health problem, A substantial percentage of infants and toddlers with CHD undergo cardiopulmonary bypass surgery. Undernutrition affects up to 90% of these patients, and it's contributed to worse surgical and neurological outcomes. Infants with CHD are typically delivered at full term with a normal birth weight. However, as time passes, their development may become stunted. There are no negotiated guidelines for nutritional monitoring and intervention in this age bracket of infants. Through the use of Energy Enriched and Protein Enriched nutrition formula during the postoperative phase, this has shown to be well tolerated and support in delivering higher nutrition intakes within the first days after surgery. Numerous clinical trials have been conducted (Zhang H et al., 2018; Scheeffer. et al., 2019) and were designed to explore the effects of early introduction of Energy Enriched and Protein Enriched formula (EP) to infants with CHD. The research found that feeding EP is correlated with improved weight gain and nutritional status, and also a decrease in Hospital Length Of Stay (HLOS) as well as antibiotic use, but this also causes increased feeding discomfort. The signs of feeding discomfort, on the other hand, were improved by medication and had little effect on feeding progress. The objective of this research is to assess the long term outcome of patients who have had energy- and protein-rich nutrition formulas post cardiac surgery.

Registry
clinicaltrials.gov
Start Date
July 21, 2021
End Date
March 12, 2024
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
King Faisal Specialist Hospital & Research Centre, Jeddah
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • infants born at term, age between 4 weeks and 12 months
  • post congenital heart surgery (RACHS score 2)

Exclusion Criteria

  • syndromic patients
  • if patient is on parenteral nutrition (PN)
  • combined inherited metabolic or chromosomal diseases
  • liver and kidney dysfunction before enrollment (index \>2 times the upper limit of normal)
  • upper GI activity, vomiting, diarrhea, bloating, and other symptoms before enrollment
  • breastfeeding patients.
  • cow's milk allergy

Outcomes

Primary Outcomes

after admission in ICU, will measure the Tolerability

Time Frame: 5 days

Gastric tolerance

Secondary Outcomes

  • Weight gain rate(90 days)

Study Sites (1)

Loading locations...

Similar Trials